Traduction de «mrsa colonisation has been associated » (Néerlandais → Français) :

However, an increased risk of clinical failure with nasal treatment of multi-site MRSA colonisation has been associated with lowlevel resistance in one study 31 .
Cependant, un risque accru d'échec clinique dans le traitement nasal de la colonisation multi-site par MRSA a été associé, dans une étude 31 , à la résistance de faible niveau.

Therefore, the cost-benefit of vigorous MRSA control policies has been grossly underestimated.
Par conséquent, le rapport coût-bénéfice de politiques vigoureuses de contrôle de MRSA est tout à fait sous-estimé.

A simple guide for veterinary pharmacovigilance has been published on the FAMHP website; together with the associated reporting form this has also been sent to all veterinarians and pharmacists.
A simple guide for veterinary pharmacovigilance has been published on the FAMHP website; together with the associated reporting form this has also been sent to all veterinarians and pharmacists.

In order to take care of monitoring, planning, coordinating and communicating about the numerous actions associated with the “FAGG-AFMPS 2008” project (see below), a support monitoring unit, the Program Management Office (PMO) unit, has been set up.
In order to take care of monitoring, planning, coordinating and communicating about the numerous actions associated with the “FAGG-AFMPS 2008” project (see below), a support monitoring unit, the Program Management Office (PMO) unit, has been set up.

Ilaris, a fully human monoclonal antibody that blocks action of the inflammatory protein interleukin-1 beta, has been launched after receiving first approvals during 2009 in the US, Europe and some other markets for treatment of cryopyrin-associated periodic syndrome (CAPS), a group of rare lifelong auto-inflammatory disorders.
Ilaris, un anticorps monoclonal entièrement humain qui bloque l’action de l’interleukine-1 bêta (IL- 1β), une protéine inflammatoire, a été lancé après avoir obtenu ses premières autorisations en 2009 aux Etats-Unis, en Europe et dans quelques autres marchés pour le traitement du syndrome périodique associé à la cryopirine (CAPS), un groupe de maladies rares auto-inflammatoires tout au long de la vie.